Therapy Directory

Sacituzumab govitecan clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Sacituzumab govitecan as a study intervention. Browse Sacituzumab govitecan recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Aug 28, 2026, 11:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

Shown on this page

Local indexed summaries

Local recruiting

The trial list below is retrieved from the live ClinicalTrials.gov search API for Sacituzumab govitecan. Results on this page are currently sorted by Recently updated.

Showing 1–12 of 58 matching trials for Sacituzumab govitecan.

Indexed local directory records.

Top conditions

Triple Negative Breast Cancer 8 Breast Cancer 7 Metastatic Breast Cancer 5 Metastatic Urothelial Carcinoma 4 Invasive Breast Carcinoma 3 Advanced Solid Tumors 2

Top sponsors

Gilead Sciences 14 National Cancer Institute (NCI) 6 Dana-Farber Cancer Institute 4 Yale University 4 H. Lee Moffitt Cancer Center and Research Institute 3 M.D. Anderson Cancer Center 3

Top locations

Boston, Massachusetts 18 Houston, Texas 17 Nashville, Tennessee 16 Chicago, Illinois 15 New York, New York 15 New Haven, Connecticut 12

Indexed official records

Open in full search

Conditions: ER-Negative Breast Cancer, HER2-negative Breast Cancer, Invasive Breast Cancer, PR-Negative Breast Cancer, Triple Negative Breast Cancer
Interventions: Pembrolizumab, Sacituzumab Govitecan; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 5
States / cities: Boston, Massachusetts • Danvers, Massachusetts • Newton, Massachusetts

Conditions: Metastatic HER2-Negative Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma
Interventions: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Sacituzumab Govitecan; Procedure · Biological
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Advanced Solid Tumors
Interventions: GS-0201, Sacituzumab Govitecan; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 4
States / cities: Boston, Massachusetts • Austin, Texas • Houston, Texas + 1 more

Conditions: Metastatic Triple-Negative Breast Cancer
Interventions: Naxitamab, Sacituzumab govitecan; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Interventions: Amrubicin (Japan only), Lurbinectedin (regions/countries where approved and available), Sacituzumab Govitecan (SG), Topotecan; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 695 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 19
States / cities: Hot Springs, Arkansas • Anaheim, California • Miami, Florida + 15 more

Conditions: Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
Interventions: Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, Docetaxel, Gemcitabine, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab, Questionnaire Administration, Sacituzumab Govitecan; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 134
States / cities: Phoenix, Arizona • Irvine, California • Orange, California + 104 more

Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Electronic Health Record Review, Enfortumab Vedotin, Immunohistochemistry Staining Method, Magnetic Resonance Imaging, Multigated Acquisition Scan, Sacituzumab Govitecan, Trastuzumab Deruxtecan; Procedure · Other · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 27
States / cities: Duarte, California • Encinitas, California • Irvine, California + 20 more

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Carboplatin, Computed Tomography, Durvalumab, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Nab-paclitaxel, Personalized Synthetic Long Peptide Vaccine, Poly ICLC, Sacituzumab Govitecan, Tremelimumab; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 30
States / cities: Orange, California • Sacramento, California • Aurora, Colorado + 22 more

Conditions: Mesothelioma, Mesothelioma; Pleura, Mesotheliomas Pleural
Interventions: Sacituzumab govitecan-hziy; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Breast Cancer, Circulating Tumor DNA, Residual Cancer, Triple Negative Breast Cancer
Interventions: Atezolizumab, Sacituzumab govitecan; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 7
States / cities: San Francisco, California • Chicago, Illinois • New Lenox, Illinois + 4 more

Conditions: Muscle-invasive Bladder Cancer, Urothelial Carcinoma
Interventions: Nivolumab, Sacituzumab Govitecan (SG); Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Orange, California

Conditions: Triple Negative Breast Cancer
Interventions: Capecitabine, Pembrolizumab, Sacituzumab govitecan-hziy (SG); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 1,514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 184
States / cities: Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 155 more

About this Sacituzumab govitecan clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Sacituzumab govitecan as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Sacituzumab govitecan.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Sacituzumab govitecan clinical trials

Filter and sort this therapy

Top conditions

Top sponsors

Top locations

Indexed official records

Sacituzumab Govitecan In TNBC

Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy

Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors

Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

A Study of Sacituzumab Govitecan in People With Mesothelioma

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

About this Sacituzumab govitecan clinical trials directory page